COLUMBIA-1: Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Trial Identifier: D910CC00001
Sponsor: MedImmune, LLC
Start Date: September 2019
Primary Completion Date: October 2022
Study Completion Date: November 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation
Spanish (US) Translation
French (Canadian) Translation
French Translation

Trial Locations

Country Location
AU Clayton, AU, 3168
AU Heidelberg, AU, 3084
AU Melbourne, AU, 3000
CA, ON Toronto, ON, CA, M5G 1X6
ES Barcelona, ES, 08035
ES Barcelona, ES, 08916
ES Madrid, ES, 28046
ES Madrid, ES, 28027
FR Nantes, FR, 44000
FR Villejuif, FR, 94805
US, CA Los Angeles, CA, US, 90095
US, CA Sacramento, CA, US, 95817
US, MI Ann Arbor, MI, US, 48109
US, NV Las Vegas, NV, US, 89169
US, NY New York, NY, US, 10065
US, OH Canton, OH, US, 44718
US, RI Providence, RI, US, 02903
US, TN Chattanooga, TN, US, 37404
US, TN Nashville, TN, US, 37203
US, TX Houston, TX, US, 77030
US, VA Charlottesville, VA, US, 22908